Immunotherapy targeting β-amyloid for Alzheimer’s disease: Research advances
10.13220/j.cnki.jipr.2016.02.005
- Author:
Yun-Zhou YU
1
Author Information
1. Institute of Biotechnology, Academy of Military Medical Sciences
- Publication Type:Journal Article
- Keywords:
Alzheimer's disease;
Antibody;
Immunotherapy;
Vaccine;
β-amyloid
- From:
Journal of International Pharmaceutical Research
2016;43(2):216-223
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease (AD) is a neurodegenerative disorder that impairs memory and cognition. The neuropathological features of the disease include neurofibrillary tangles, deposition of β-amyloid (Aβ) in senile plaques and neuronal loss in affected brain regions. The amyloid cascade hypothesis suggests that production and accumulation of excessive β- amyloid may be the main cause of the onset and progression of Alzheimer's disease. Active and passive immunotherapy targeting β- amyloid may be the most promising strategy to prevent or treat AD. This review seeks to put perspective to the mixed results obtained so far in pre-clinical and clinical trials of AD vaccines and antibodies targeting β-amyloid and discusses the perspective and novel direction of successful AD immunotherapy. Novel strategies for the design of more effective therapeutic vaccines are suggested.
